CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VBI Vaccines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VBI Vaccines Inc
160 Second Street, Cambridge
Phone: (617) 830-3031p:617 830-3031 CAMBRIDGE, MA  02142  United States Fax: +972 89480660f:+972 89480660
Emerged from Bankruptcy on 1/3/2025
On 1/3/2025, VBI Vaccines Inc., VBI Vaccines (Delaware) Inc. and Variation Biotechnologies Inc. emerged from the CCAA proceedings
On 7/30/2024, VBI Vaccines Inc filed a Chapter 15 Bankruptcy Petition #24-11625 in the U.S. Bankruptcy Court for the District of Delaware in order to gain recognition of its CCAA proceedings dated 7/29/2024
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Steven H.Gillis 71 5/1/2016 5/1/2016
President, Chief Executive Officer, Director Jeffrey R.Baxter 62 5/1/2016 5/1/2016
Chief Financial Officer, Director, Head of Corporate Development NellBeattie 36 4/10/2023 9/1/2017
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Variation Biotechnologies
Variation Biotechnologies (US), Inc.
Variation Biotechnologies Inc.
VBI Vaccines (Delaware) Inc.
VBI Vaccines B.V
VBI Vaccines Inc

General Information
Number of Employees: 131 (As of 12/31/2023)
Outstanding Shares: 28,682,275 (As of 5/15/2024)
Shareholders: 247
Stock Exchange: OTC
Fax Number: +972 89480660


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025